PDCD1 and neoplasm: Similar results for tumor growth were observed for LLC subcutaneous tumors [Tumor Volume (mm3): Day 21: Control: 852.4 ± 470.6, Anti-PD-1: 1313 ± 461.1 TRAM: 419.7 ± 306.6, TRAM + Anti-PD-1: 354.7 ± 186.4; Day 26: TRAM: 961 ± 654.7, TRAM + anti-PD-1: 364 ± 201] (Fig. 5B).